Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Vasculitis 1Prostatic Neoplasms 1Neoplasm Metastasis 1Metabolic Syndrome 1Lung Neoplasms 1Inflammation 1Granulomatosis with Polyangiitis 1Bone Neoplasms 1Arthritis, Juvenile 1

Interventions

Gemcitabine 5Capecitabine 4pembrolizumab 3Fluorouracil 3Cisplatin 3vinflunine 2enzalutamide 2cabazitaxel 2abiraterone 2Ipilimumab 2Haloperidol 2Androgen Antagonists 2vedolizumab 1trifluridine tipiracil drug combination 1relugolix 1racemetyrosine 1nimotuzumab 1nilutamide 1lanreotide 1histrelin 1futibatinib 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1bicalutamide 1beta-Glucans 1auricularum 1atezolizumab 1apatinib 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × Etanercept × Clear all
NCT00127387 2012-06-26

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

The University of Texas Health Science Center at San Antonio

Phase 2/3 Terminated
54 enrolled
GenitourinarySarcomaThoracic

Bone Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡